Kidney, heart and brain: Three organs targeted by ageing and glycation

Clinical Science

Volumn 131, Issue 11, 2017, Pages 1069-1092

  Frimat, Marie ^a,b   Daroux, Maité ^a,c   Litke, Rachel ^a,b   Nevière, Rémi ^a,b   Tessier, Frédéric J ^a   Boulanger, Eric ^a,b  

^a UNIV LILLE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c Department of Nephrology Duchenne Hospital   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; AGER PROTEIN, HUMAN;

AGING; BRAIN; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DEGENERATIVE DISEASE; DEMENTIA; GLYCATION; HEART; HEART DISEASE; HEART INJURY; HUMAN; HYPERGLYCEMIA; IN VIVO STUDY; KIDNEY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; ANTAGONISTS AND INHIBITORS; DIET; GLYCOSYLATION; HEART DISEASES; METABOLISM; MOLECULARLY TARGETED THERAPY; NEURODEGENERATIVE DISEASES; PROCEDURES; RENAL INSUFFICIENCY, CHRONIC;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; AGING; DIET; GLYCOSYLATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HEART DISEASES; HUMANS; MOLECULAR TARGETED THERAPY; NEURODEGENERATIVE DISEASES; RENAL INSUFFICIENCY, CHRONIC;

EID: 85020235257     PISSN: 01435221     EISSN: 14708736     Source Type: Journal    
DOI: 10.1042/CS20160823     Document Type: Review

References (250)

1. Maillard, L. (1912) Action des acides aminés sur les sucres: formation des mélanöidines par voie méthodique [in French]. C. R. Acad. Sci. 154, 66
2. Tessier, F.J. (2010) The Maillard reaction in the human body. The main discoveries and factors that affect glycation. Pathol. Biol. (Paris) 58, 214-2149
3. Delgado-Andrade, C. (2016) Carboxymethyl-lysine: thirty years of investigation in the field of AGE formation. Food Funct. 7, 46-57
4. Kunkel, H.G. and Wallenius, G. (1955) New hemoglobin in normal adult blood. Science 122, 288
5. Rahbar, S. (1968) An abnormal hemoglobin in red cells of diabetics. Clin. Chim. Acta 22, 296-298
6. Cerami, A. (1986) Aging of proteins and nucleic acids: what is the role of glucose. Trends Biochem. Sci. 11, 311-314
7. Uribarri, J., del Castillo, M.D., de la Maza, M.P., Filip, R., Gugliucci, A., Luevano-Contreras, C. et al. (2015) Dietary advanced glycation end products and their role in health and disease. Adv. Nutr. 6, 461-473
8. Ott, C., Jacobs, K., Haucke, E., Navarrete Santos, A., Grune, T. and Simm, A. (2014) Role of advanced glycation end products in cellular signaling. Redox Biol. 2, 411-429
9. Roca, F., Grossin, N., Chassagne, P., Puisieux, F. and Boulanger, E. (2014) Glycation: the angiogenic paradox in aging and age-related disorders and diseases. Ageing Res. Rev. 15, 146-160
10. Van Puyvelde, K., Mets, T., Njemini, R., Beyer, I. and Bautmans, I. (2014) Effect of advanced glycation end product intake on inflammation and aging: a systematic review. Nutr. Rev. 72, 638-650
11. Simm, A., Müller, B., Nass, N., Hofmann, B., Bushnaq, H., Silber, R.-E. et al. (2015) Protein glycation-Between tissue aging and protection. Exp. Gerontol. 68, 71-75
12. Grossin, N., Auger, F., Niquet-Leridon, C., Durieux, N., Montaigne, D., Schmidt, A.M. et al. (2015) Dietary CML-enriched protein induces functional arterial aging in a RAGE-dependent manner in mice. Mol. Nutr. Food Res. 59, 927-938
13. Wang, Z., Jiang, Y., Liu, N., Ren, L., Zhu, Y., An, Y. et al. (2012) Advanced glycation end-product Ne-carboxymethyl-Lysine accelerates progression of atherosclerotic calcification in diabetes. Atherosclerosis 221, 387-396
14. Yaffe, K., Lindquist, K., Schwartz, A.V., Vitartas, C., Vittinghoff, E., Satterfield, S. et al. (2011) Advanced glycation end product level, diabetes, and accelerated cognitive aging. Neurology 77, 1351-1356
15. Vistoli, G., De Maddis, D., Cipak, A., Zarkovic, N., Carini, M. and Aldini, G. (2013) Advanced glycoxidation and lipoxidation end products (AGEs and ALEs): an overview of their mechanisms of formation. Free Radic. Res. 47 (sup1), 3-27
16. He, C., Sabol, J., Mitsuhashi, T. and Vlassara, H. (1999) Dietary glycotoxins: inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration. Diabetes 48, 1308-1315
17. Thornalley, P.J., Battah, S., Ahmed, N., Karachalias, N., Agalou, S., Babaei-Jadidi, R. et al. (2003) Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem. J. 375 (Pt 3), 581-592
18. Rabbani, N. and Thornalley, P.J. (2015) Hidden complexities in the measurement of fructosyl-lysine and advanced glycation end products for risk prediction of vascular complications of diabetes. Diabetes 64, 9-11
19. Bunn, H.F. and Higgins, P.J. (1981) Reaction of monosaccharides with proteins: possible evolutionary significance. Science 213, 222-224
20. Thornalley, P.J. (2005) Dicarbonyl intermediates in the maillard reaction. Ann. N.Y. Acad. Sci. 1043, 111-117
21. Henning, C. and Glomb, M.A. (2016) Pathways of the Maillard reaction under physiological conditions. Glycoconj. J. 33, 499-512
22. Rabbani, N., Xue, M. and Thornalley, P.J. (2016) Dicarbonyls and glyoxalase in disease mechanisms and clinical therapeutics. Glycoconj. J. 33, 513-525
23. Dyer, D.G., Blackledge, J.A., Katz, B.M., Hull, C.J., Adkisson, H.D., Thorpe, S.R. et al. (1991) The Maillard reaction in vivo. Z Ernährungswiss. 30, 29-45
24. Van Schaftingen, E., Collard, F., Wiame, E. and Veiga-da-Cunha, M. (2012) Enzymatic repair of Amadori products. Amino Acids 42, 1143-1150
25. Deppe, V.M., Bongaerts, J., O'Connell, T., Maurer, K.-H. and Meinhardt, F. (2011) Enzymatic deglycation of Amadori products in bacteria: mechanisms, occurrence and physiological functions. Appl. Microbiol. Biotechnol. 90, 399-406
26. Vlassara, H. (2001) The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab. Res. Rev. 17, 436-443
27. Ohgami, N., Nagai, R., Ikemoto, M., Arai, H., Miyazaki, A., Hakamata, H. et al. (2002) CD36, serves as a receptor for advanced glycation endproducts (AGE). J. Diabetes Complications 16, 56-59
28. Horiuchi, S., Sakamoto, Y. and Sakai, M. (2003) Scavenger receptors for oxidized and glycated proteins. Amino Acids 25, 283-292
29. Grimm, S., Horlacher, M., Catalgol, B., Hoehn, A., Reinheckel, T. and Grune, T. (2012) Cathepsins D and L reduce the toxicity of advanced glycation end products. Free Radic. Biol. Med. 52, 1011-1023
30. Tessier, F., Obrenovich, M. and Monnier, V.M. (1999) Structure and mechanism of formation of human lens fluorophore LM-1. Relationship to vesperlysine A and the advanced Maillard reaction in aging, diabetes, and cataractogenesis. J. Biol. Chem. 274, 20796-20804
31. Smuda, M., Henning, C., Raghavan, C.T., Johar, K., Vasavada, A.R., Nagaraj, R.H. et al. (2015) Comprehensive analysis of maillard protein modifications in human lenses: effect of age and cataract. Biochemistry 54, 2500-2507
32. Dyer, D.G., Dunn, J.A., Thorpe, S.R., Bailie, K.E., Lyons, T.J., McCance, D.R. et al. (1993) Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J. Clin. Invest. 91, 2463-2469
33. Glomb, M.A. and Lang, G. (2001) Isolation and characterization of glyoxal-arginine modifications. J. Agric. Food Chem. 49, 1493-1501
34. Ahmed, N., Argirov, O.K., Minhas, H.S., Cordeiro, C.A.A. and Thornalley, P.J. (2002) Assay of advanced glycation endproducts (AGEs): surveying AGEs by chromatographic assay with derivatization by 6-aminoquinolyl-N-hydroxysuccinimidyl-carbamate and application to Nepsilon-carboxymethyl-lysineand Nepsilon-(1-carboxyethyl)lysine-modified albumin. Biochem. J. 364 (Pt 1), 1-14
35. Klöpfer, A., Spanneberg, R. and Glomb, M.A. (2011) Formation of arginine modifications in a model system of Na-tert-butoxycarbonyl (Boc)-arginine with methylglyoxal. J. Agric. Food Chem. 59, 394-401
36. Biemel, K.M. (2002) Identification and quantification of major Maillard cross-links in human serum albumin and lens protein. Evidence for glucosepane as the dominant compound. J. Biol. Chem. 277, 24907-24915
37. Verzijl, N., DeGroot, J., Thorpe, S.R., Bank, R.A., Shaw, J.N., Lyons, T.J. et al. (2000) Effect of collagen turnover on the accumulation of advanced glycation end products. J. Biol. Chem. 275, 39027-39031
38. Baynes, J.W. and Thorpe, S.R. (2000) Glycoxidation and lipoxidation in atherogenesis. Free Radic. Biol. Med. 28, 1708-1716
39. Chondrogianni, N., Petropoulos, I., Grimm, S., Georgila, K., Catalgol, B., Friguet, B. et al. (2014) Protein damage, repair and proteolysis. Mol. Aspects Med. 35, 1-71
40. Uchiki, T., Weikel, K.A., Jiao, W., Shang, F., Caceres, A., Pawlak, D. et al. (2012) Glycation-altered proteolysis as a pathobiologic mechanism that links dietary glycemic index, aging, and age-related disease (in nondiabetics). Aging Cell 11, 1-13
41. Queisser, M.A., Yao, D., Geisler, S., Hammes, H-P, Lochnit, G., Schleicher, E.D. et al. (2010) Hyperglycemia impairs proteasome function by methylglyoxal. Diabetes 59, 670-678
42. Miyata, T., Ueda, Y., Horie, K., Nangaku, M., Tanaka, S., van Ypersele de Strihou, C. et al. (1998) Renal catabolism of advanced glycation end products: the fate of pentosidine. Kidney Int 53, 416-422
43. Gugliucci, A. and Bendayan, M. (1996) Renal fate of circulating advanced glycated end products (AGE): evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells. Diabetologia 39, 149-160
44. Asano, M., Fujita, Y., Ueda, Y., Suzuki, D., Miyata, T., Sakai, H. et al. (2002) Renal proximal tubular metabolism of protein-linked pentosidine, an advanced glycation end product. Nephron 91, 688-694
45. Makita, Z., Radoff, S., Rayfield, E.J., Yang, Z., Skolnik, E., Delaney, V. et al. (1991) Advanced glycosylation end products in patients with diabetic nephropathy. N. Engl. J. Med. 325, 836-842
46. Miyata, T., Ueda, Y., Shinzato, T., Iida, Y., Tanaka, S., Kurokawa, K. et al. (1996) Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine. J. Am. Soc. Nephrol. 7, 1198-1206
47. Kratochvilová, M., Zakiyanov, O., Kalousová, M., Kŕiha, V., Zima, T. and Tesar V. (2011) Associations of serum levels of advanced glycation end products with nutrition markers and anemia in patients with chronic kidney disease. Ren. Fail. 33, 131-137
48. Agalou, S., Ahmed, N., Babaei-Jadidi, R., Dawnay, A. and Thornalley, P.J. (2005) Profound mishandling of protein glycation degradation products in uremia and dialysis. J. Am. Soc. Nephrol. 16, 1471-185
49. Antolini, F., Valente, F., Ricciardi, D. and Fagugli, R.M. (2004) Normalization of oxidative stress parameters after kidney transplant is secondary to full recovery of renal function. Clin. Nephrol. 62, 131-137
50. Finot, P.A. and Magnenat, E. (1981) Metabolic transit of early and advanced Maillard products. Prog. Food Nutr. Sci. 5, 193-207
51. Lyons, T.J. (2002) Glycation, carbonyl stress, EAGLEs, and the vascular complications of diabetes. Semin. Vasc. Med. 2, 175-189
52. Stinghen, A.E.M., Massy, Z.A., Vlassara, H., Striker, G.E. and Boullier, A. (2016) Uremic toxicity of advanced glycation end products in CKD. J. Am. Soc. Nephrol. 27, 354-370
53. Schleicher, E.D., Wagner, E. and Nerlich, A.G. (1997) Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J. Clin. Invest. 99, 457-468
54. Horie, K., Miyata, T., Maeda, K., Miyata, S., Sugiyama, S., Sakai, H. et al. (1997) Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. J. Clin. Invest. 100, 2995-3004
55. Tessier, F.J. and Birlouez-Aragon, I. (2012) Health effects of dietary Maillard reaction products: the results of ICARE and other studies. Amino Acids 42, 1119-1131
56. Tessier, F.J., Niquet-Léridon, C., Jacolot, P., Jouquand, C., Genin, M., Schmidt, A.-M. et al. (2016) Quantitative assessment of organ distribution of dietary protein-bound (13) C-labeled N(?) -carboxymethyllysine after a chronic oral exposure in mice. Mol. Nutr. Food Res. 60, 2446-2456
57. Semba, R.D., Nicklett, E.J. and Ferrucci, L. (2010) Does accumulation of advanced glycation end products contribute to the aging phenotype. J. Gerontol. A Biol. Sci. Med. Sci. 65, 963-975
58. Koschinsky, T., He, C.J., Mitsuhashi, T., Bucala, R., Liu, C., Buenting, C. et al. (1997) Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc. Natl. Acad. Sci. U.S.A. 94, 6474-6479
59. Henle, T. (2005) Protein-bound advanced glycation endproducts (AGEs) as bioactive amino acid derivatives in foods. Amino Acids 29, 313-322
60. Litwinoff, E., Hurtado Del Pozo, C., Ramasamy, R. and Schmidt, A.M. (2015) Emerging targets for therapeutic development in diabetes and its complications: the RAGE signaling pathway. Clin. Pharmacol. Ther. 98, 135-144
61. He, W., Zhang, J., Gan, T., Xu, G. and Tang, B. (2015) Advanced glycation end products induce endothelial-to-mesenchymal transition via downregulating Sirt 1 and upregulating TGF-ß in human endothelial cells. BioMed. Res. Int. 2015, 684242
62. Bai, Y.-H., Wang, J.-P., Yang, M., Zeng, Y. and Jiang, H.-Y. (2015) SiRNA-HMGA2 weakened AGEs-induced epithelial-to-mesenchymal transition in tubular epithelial cells. Biochem. Biophys. Res. Commun. 457, 730-735
63. Monnier, V.M., Vishwanath, V., Frank, K.E., Elmets, C.A., Dauchot, P. and Kohn, R.R. (1986) Relation between complications of type I diabetes mellitus and collagen-linked fluorescence. N. Engl. J. Med. 314, 403-408
64. Roncero-Ramos, I., Niquet-Léridon, C., Strauch, C., Monnier, V.M., Tessier, F.J., Navarro, M.P. et al. (2014) An advanced glycation end product (AGE)-rich diet promotes Nε-carboxymethyl-lysine accumulation in the cardiac tissue and tendons of rats. J. Agric. Food. Chem. 62, 6001-6006
65. Henle, T. (2007) Dietary advanced glycation end products-a risk to human health? A call for an interdisciplinary debate. Mol. Nutr. Food Res. 51, 1075-1078
66. Alamir, I., Niquet-Leridon, C., Jacolot, P., Rodriguez, C., Orosco, M., Anton, P.M. et al. (2013) Digestibility of extruded proteins and metabolic transit of N ε-carboxymethyllysine in rats. Amino Acids 44, 1441-1449
67. Clarke, R.E., Dordevic, A.L., Tan, S.M., Ryan, L. and Coughlan, M.T. (2016) Dietary advanced glycation end products and risk factors for chronic disease: a systematic review of randomised controlled trials. Nutrients 8, 125
68. Daroux, M., Prévost, G., Maillard-Lefebvre, H., Gaxatte, C., D'Agati, V.D., Schmidt, A.M. et al. (2010) Advanced glycation end-products: implications for diabetic and non-diabetic nephropathies. Diabetes Metab. 36, 1-10
69. Uribarri, J. and He, J.C. (2015) The low AGE diet: a neglected aspect of clinical nephrology practice. Nephron 130, 48-53
70. Kawanami, D., Matoba, K. and Utsunomiya, K. (2016) Signaling pathways in diabetic nephropathy. Histol. Histopathol. 31, 1059-1067
71. Hagiwara, S., McClelland, A. and Kantharidis, P. (2013) MicroRNA in diabetic nephropathy: renin angiotensin, aGE/RAGE, and oxidative stress pathway. J. Diabetes Res. 2013, 173783
72. Zhuang, A. and Forbes, J.M. (2016) Diabetic kidney disease: a role for advanced glycation end-product receptor 1 (AGE-R1). Glycoconj. J. 33, 645-652
73. Vlassara, H., Striker, L.J., Teichberg, S., Fuh, H., Li, Y.M. and Steffes, M. (1994) Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc. Natl. Acad. Sci. U.S.A. 91, 11704-11708
74. Yamamoto, Y., Kato, I., Doi, T., Yonekura, H., Ohashi, S., Takeuchi, M. et al. (2001) Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J. Clin. Invest. 108, 261-268
75. Nakamura, S., Makita, Z., Ishikawa, S., Yasumura, K., Fujii, W., Yanagisawa, K. et al. (1997) Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 46, 895-899
76. Forbes, J.M., Thallas, V., Thomas, M.C., Founds, H.W., Burns, W.C., Jerums, G. et al. (2003) The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J. 17, 1762-1764
77. Park, J., Kwon, M.K., Huh, J.Y., Choi, W.J., Jeong, L.S., Nagai, R. et al. (2011) Renoprotective antioxidant effect of alagebrium in experimental diabetes. Nephrol. Dial. Transplant. 26, 3474-3484
78. Berg, T.J., Bangstad, H.J., Torjesen, P.A., Osterby, R., Bucala, R. and Hanssen, K.F. (1997) Advanced glycation end products in serum predict changes in the kidney morphology of patients with insulin-dependent diabetes mellitus. Metabolism 46, 661-665
79. Thomas, M.C., Woodward, M., Neal, B., Li, Q., Pickering, R., Marre, M. et al. (2015) Relationship between levels of advanced glycation end products and their soluble receptor and adverse outcomes in adults with type 2 diabetes. Diabetes Care 38, 1891-1897
80. Beisswenger, P.J., Moore, L.L., Brinck-Johnsen, T. and Curphey, T.J. (1993) Increased collagen-linked pentosidine levels and advanced glycosylation end products in early diabetic nephropathy. J. Clin. Invest. 92, 212-217
81. Genuth, S., Sun, W., Cleary, P., Sell, D.R., Dahms, W., Malone, J. et al. (2005) Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes 54, 3103-3111
82. Bolton, W.K., Cattran, D.C., Williams, M.E., Adler, S.G., Appel, G.B., Cartwright, K. et al. (2004) Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am. J. Nephrol. 24, 32-40
83. Alkhalaf, A., Kleefstra, N., Groenier, K.H., Bilo, H.J.G., Gans, R.O.B., Heeringa, P. et al. (2012) Effect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathy. PloS One 7, e40427
84. Alkhalaf, A., Klooster, A., van Oeveren, W., Achenbach, U., Kleefstra, N., Slingerland, R.J. et al. (2010) A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care 33, 1598-1601
85. Williams, M.E., Bolton, W.K., Khalifah, R.G., Degenhardt, T.P., Schotzinger, R.J. and McGill, J.B. (2007) Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am. J. Nephrol. 27, 605-614
86. Tanji, N., Markowitz, G.S., Fu, C., Kislinger, T., Taguchi, A., Pischetsrieder, M. et al. (2000) Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J. Am. Soc. Nephrol. 11, 1656-1666
87. Martens, H.A., Nienhuis, H.L.A., Gross, S., van der Steege, G., Brouwer, E., Berden, J.H.M. et al. (2012) Receptor for advanced glycation end products (RAGE) polymorphisms are associated with systemic lupus erythematosus and disease severity in lupus nephritis. Lupus 21, 959-968
88. Miyata, T., Ueda, Y., Yamada, Y., Izuhara, Y., Wada, T., Jadoul, M. et al. (1998) Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end product: carbonyl stress in uremia. J. Am. Soc. Nephrol. 9, 2349-2356
89. Müller-Krebs, S., Kihm, L.P., Zeier, B., Gross, M.L., Deppisch, R., Wieslander, A. et al. (2008) Renal toxicity mediated by glucose degradation products in a rat model of advanced renal failure. Eur. J. Clin. Invest. 38, 296-305
90. Li, M., Zeng, M., He, Z., Zheng, Z., Qin, F., Tao, G. et al. (2015) Increased accumulation of protein-bound N(e)-(carboxymethyl)lysine in tissues of healthy rats after chronic oral N(e)-(carboxymethyl)lysine. J. Agric. Food Chem. 63, 1658-1663
91. Sebeková, K., Hofmann, T., Boor, P., Sebeková, K., Ulicná, O., Erbersdobler, H.F. et al. (2005) Renal effects of oral maillard reaction product load in the form of bread crusts in healthy and subtotally nephrectomized rats. Ann. N.Y. Acad. Sci. 1043, 482-491
92. Zheng, F., He, C., Cai, W., Hattori, M., Steffes, M. and Vlassara, H. (2002) Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products. Diabetes Metab. Res. Rev. 18, 224-237
93. Feng, J.X., Hou, F.F., Liang, M., Wang, G.B., Zhang, X., Li, H.Y. et al. (2007) Restricted intake of dietary advanced glycation end products retards renal progression in the remnant kidney model. Kidney Int. 71, 901-911
94. Vlassara, H., Cai, W., Goodman, S., Pyzik, R., Yong, A., Chen, X. et al. (2009) Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: role of the antiinflammatory AGE receptor-1. J. Clin. Endocrinol. Metab. 94, 4483-4491
95. Uribarri, J., Peppa, M., Cai, W., Goldberg, T., Lu, M., He, C. et al. (2003) Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J. Am. Soc. Nephrol. 14, 728-731
96. Abel, M., Ritthaler, U., Zhang, Y., Deng, Y., Schmidt, A.M., Greten, J. et al. (1995) Expression of receptors for advanced glycosylated end-products in renal disease. Nephrol. Dial. Transplant. 10, 1662-1667
97. Pala, L., Cresci, B., Manuelli, C., Maggi, E., Yamaguchi, Y.F., Cappugi, P. et al. (2005) Vascular endothelial growth factor receptor-2 and low affinity VEGF binding sites on human glomerular endothelial cells: Biological effects and advanced glycosilation end products modulation. Microvasc. Res. 70, 179-188
98. Matsui, T., Nishino, Y., Maeda, S., Takeuchi, M. and Yamagishi, S. (2011) Irbesartan inhibits advanced glycation end product (AGE)-induced up-regulation of vascular cell adhesion molecule-1 (VCAM-1) mRNA levels in glomerular endothelial cells. Microvasc. Res. 81, 269-273
99. Luo, P., Peng, H., Li, C., Ye, Z., Tang, H., Tang, Y. et al. (2015) Advanced glycation end products induce glomerular endothelial cell hyperpermeability by upregulating matrix metalloproteinase activity. Mol. Med. Rep. 11, 4447-4453
100. Lan, L., Han, Y., Ren, W., Jiang, J., Wang, P. and Hu, Z. (2015) Advanced glycation end-products affect the cytoskeletal structure of rat glomerular endothelial cells via the Ras-related C3 botulinum toxin substrate 1 signaling pathway. Mol. Med. Rep. 11, 4321-4326
101. Rüster, C., Bondeva, T., Franke, S., Förster, M. and Wolf, G. (2008) Advanced glycation end-products induce cell cycle arrest and hypertrophy in podocytes. Nephrol. Dial. Transplant. 23, 2179-2191
102. Chuang, P.Y., Yu, Q., Fang, W., Uribarri, J. and He, J.C. (2007) Advanced glycation endproducts induce podocyte apoptosis by activation of the FOXO4 transcription factor. Kidney Int. 72, 965-976
103. Rong, G., Tang, X., Guo, T., Duan, N., Wang, Y., Yang, L. et al. (2015) Advanced oxidation protein products induce apoptosis in podocytes through induction of endoplasmic reticulum stress. J. Physiol. Biochem. 71, 455-470
104. Zhou, L.L., Cao, W., Xie, C., Tian, J., Zhou, Z., Zhou, Q. et al. (2012) The receptor of advanced glycation end products plays a central role in advanced oxidation protein products-induced podocyte apoptosis. Kidney Int. 82, 759-770
105. Doublier, S., Salvidio, G., Lupia, E., Ruotsalainen, V., Verzola, D., Deferrari, G. et al. (2003) Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II. Diabetes 52, 1023-1030
106. Cheng, C.L., Tang, Y., Zheng, Z., Liu, X., Ye, Z.C., Wang, C. et al. (2012) Advanced glycation end-products activate the renin-angiotensin system through the RAGE/PI3-K signaling pathway in podocytes. Clin. Invest. Med. 35, E282
107. Ha, T.-S. (2006) High glucose and advanced glycosylated end-products affect the expression of alpha-actinin-4 in glomerular epithelial cells. Nephrology (Carlton) 11, 435-441
108. Bondeva, T., Rüster, C., Franke, S., Hammerschmid, E., Klagsbrun, M., Cohen, C.D. et al. (2009) Advanced glycation end-products suppress neuropilin-1 expression in podocytes. Kidney Int. 75, 605-616
109. Bondeva, T., Wojciech, S. and Wolf, G. (2011) Advanced glycation end products inhibit adhesion ability of differentiated podocytes in a neuropilin-1-dependent manner. Am. J. Physiol. Renal. Physiol. 301, F852-F870
110. McRobert, E.A. and Bach, L.A. (2016) Ezrin contributes to impaired podocyte migration and adhesion caused by advanced glycation end products. Nephrology (Carlton) 21, 13-20
111. Kimura, M., Toyoda, M., Kato, M., Kobayashi, K., Abe, M., Kobayashi, T. et al. (2008) Expression of alpha-actinin-4 in human diabetic nephropathy. Intern. Med. Tokyo Jpn 47, 1099-1106
112. Holderied, A., Romoli, S., Eberhard, J., Konrad, L.A., Devarapu, S.K., Marschner, J.A. et al. (2015) Glomerular parietal epithelial cell activation induces collagen secretion and thickening of Bowman's capsule in diabetes. Lab. Invest. J. Tech. Methods Pathol. 95, 273-282
113. Kumar, P.A., Welsh, G.I., Raghu, G., Menon, R.K., Saleem, M.A. and Reddy, G.B. (2016) Carboxymethyl lysine induces EMT in podocytes through transcription factor ZEB2: Implications for podocyte depletion and proteinuria in diabetes mellitus. Arch. Biochem. Biophys. 590, 10-19
114. Meek, R.L., LeBoeuf, R.C., Saha, S.A., Alpers, C.E., Hudkins, K.L., Cooney, S.K. et al. (2013) Glomerular cell death and inflammation with high-protein diet and diabetes. Nephrol. Dial. Transplant. 28, 1711-1720
115. Brizzi, M.F., Dentelli, P., Rosso, A., Calvi, C., Gambino, R., Cassader, M. et al. (2004) RAGE- and TGF-beta receptor-mediated signals converge on STAT5 and p21waf to control cell-cycle progression of mesangial cells: a possible role in the development and progression of diabetic nephropathy. FASEB J. 18, 1249-1251
116. Yamagishi, S., Inagaki, Y., Okamoto, T., Amano, S., Koga, K., Takeuchi, M. et al. (2002) Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J. Biol. Chem. 277, 20309-20315
117. Gao, L., Huang, W. and Li, J. (2013) NOX1 abet mesangial fibrogenesis via iNOS induction in diabetes. Mol. Cell Biochem. 382, 185-191
118. Huang, K., Chen, C., Hao, J., Huang, J., Wang, S., Liu, P. et al. (2015) Polydatin promotes Nrf2-ARE anti-oxidative pathway through activating Sirt1 to resist AGEs-induced upregulation of fibronetin and transforming growth factor-ß1 in rat glomerular messangial cells. Mol. Cell Endocrinol. 399, 178-189
119. Wang, X., McLennan, S.V. and Twigg, S.M. (2011) CCN-2 is up-regulated by and mediates effects of matrix bound advanced glycated end-products in human renal mesangial cells. J. Cell Commun. Signal. 5, 193-200
120. Yuan, Y., Zhao, L., Chen, Y., Moorhead, J.F., Varghese, Z., Powis, S.H. et al. (2011) Advanced glycation end products (AGEs) increase human mesangial foam cell formation by increasing Golgi SCAP glycosylation in vitro. Am. J. Physiol. Renal. Physiol. 301, F236-F243
121. Gilbert, R.E. and Cooper, M.E. (1999) The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury. Kidney Int. 56, 1627-1637
122. Tang, S.C.W. and Lai, K.N. (2012) The pathogenic role of the renal proximal tubular cell in diabetic nephropathy. Nephrol. Dial. Transplant. 27, 3049-3056
123. Ozdemir, A.M., Hopfer, U., Rosca, M.V., Fan, X.-J., Monnier, V.M. and Weiss, M.F. (2008) Effects of advanced glycation end product modification on proximal tubule epithelial cell processing of albumin. Am. J. Nephrol. 28, 14-24
124. Gallicchio, M.A. and Bach, L.A. (2013) Uptake of advanced glycation end products by proximal tubule epithelial cells via macropinocytosis. Biochim. Biophys. Acta 1833, 2922-2932
125. Li, J.H., Wang, W., Huang, X.R., Oldfield, M., Schmidt, A.M., Cooper, M.E. et al. (2004) Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway. Am. J. Pathol. 164, 1389-1397
126. Oldfield, M.D., Bach, L.A., Forbes, J.M., Nikolic-Paterson, D., McRobert, A., Thallas, V. et al. (2001) Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J. Clin. Invest. 108, 1853-1863
127. Cheng, M., Liu, H., Zhang, D., Liu, Y., Wang, C., Liu, F. et al. (2015) HMGB1 enhances the AGE-induced expression of CTGF and TGF-β via RAGE-dependent signaling in renal tubular epithelial cells. Am. J. Nephrol. 41, 257-266
128. Goldin, A., Beckman, J.A., Schmidt, A.M. and Creager, M.A. (2006) Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation. 114, 597-605
129. Taki, K., Takayama, F., Tsuruta, Y. and Niwa, T. (2006) Oxidative stress, advanced glycation end product, and coronary artery calcification in hemodialysis patients. Kidney Int. 70, 218-224
130. Ueno, H., Koyama, H., Fukumoto, S., Tanaka, S., Shoji, T., Shoji, T. et al. (2011) Advanced glycation end products, carotid atherosclerosis, and circulating endothelial progenitor cells in patients with end-stage renal disease. Metabolism 60, 453-459
131. Jiang, J., Chen, P., Chen, J., Yu, X., Xie, D., Mei, C. et al. (2012) Accumulation of tissue advanced glycation end products correlated with glucose exposure dose and associated with cardiovascular morbidity in patients on peritoneal dialysis. Atherosclerosis 224, 187-194
132. Sell, D.R. and Monnier, V,M. (2012) Molecular basis of arterial stiffening: role of glycation-a mini-review. Gerontology 58, 227-237
133. Bucala, R., Makita, Z., Vega, G., Grundy, S., Koschinsky, T., Cerami, A. et al. (1994) Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc. Natl. Acad. Sci. U.S.A. 91, 9441-9445
134. Makita, Z., Yanagisawa, K., Kuwajima, S., Bucala, R., Vlassara, H. and Koike, T. (1996) The role of advanced glycosylation end-products in the pathogenesis of atherosclerosis. Nephrol. Dial. Transplant. 11 (Suppl 5), 31-33
135. Neviere, R., Yu, Y., Wang, L., Tessier, F. and Boulanger, E. (2016) Implication of advanced glycation end products (Ages) and their receptor (Rage) on myocardial contractile and mitochondrial functions. Glycoconj. J. 33, 607-617
136. Prasad, C., Imrhan, V., Marotta, F., Juma, S. and Vijayagopal, P. (2014) Lifestyle and advanced glycation end products (AGEs) burden: its relevance to healthy aging. Aging Dis. 5, 212-217
137. Simm, A. (2013) Protein glycation during aging and in cardiovascular disease. J. Proteomics 92, 248-259
138. Bodiga, V.L., Eda, S.R. and Bodiga, S. (2014) Advanced glycation end products: role in pathology of diabetic cardiomyopathy. Heart Fail. Rev. 19, 49-63
139. Bucciarelli, L.G., Ananthakrishnan, R., Hwang, Y.C., Kaneko, M., Song, F., Sell, D.R. et al. (2008) RAGE and modulation of ischemic injury in the diabetic myocardium. Diabetes 57, 1941-1951
140. Brett, J., Schmidt, A.M., Yan, S.D., Zou, Y.S., Weidman, E., Pinsky, D. et al. (1993) Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am. J. Pathol. 143, 1699-1712
141. Schäfer, S., Huber, J., Wihler, C., Rütten, H., Busch, A.E. and Linz, W. (2006) Impaired left ventricular relaxation in type 2 diabetic rats is related to myocardial accumulation of N ? -(carboxymethyl) lysine. Eur. J. Heart Fail. 8, 2-6
142. Norton, G.R., Candy, G. and Woodiwiss, A.J. (1996) Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats. Circulation 93, 1905-1912
143. Liu, J., Masurekar, M.R., Vatner, D.E., Jyothirmayi, G.N., Regan, T.J., Vatner, S.F. et al. (2003) Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart. Am. J. Physiol. Heart Circ. Physiol. 285, H2587-H2591
144. Fukami, K., Yamagishi, S.-I. and Okuda, S. (2014) Role of AGEs-RAGE system in cardiovascular disease. Curr. Pharm. Des. 20, 2395-2402
145. Barlovic, D.P., Soro-Paavonen, A. and Jandeleit-Dahm, K.A.M. (2011) RAGE biology, atherosclerosis and diabetes. Clin. Sci. Lond. 121, 43-55
146. Ramasamy, R. and Schmidt, A.M. (2012) Receptor for advanced glycation end products (RAGE) and implications for the pathophysiology of heart failure. Curr. Heart Fail. Rep. 9, 107-116
147. Ward, M.S., Fortheringham, A.K., Cooper, M.E. and Forbes, J.M. (2013) Targeting advanced glycation endproducts and mitochondrial dysfunction in cardiovascular disease. Curr. Opin. Pharmacol. 13, 654-661
148. Yan, S.F., Ramasamy, R. and Schmidt, A.M. (2009) The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease. Expert Rev. Mol. Med. 11, e9
149. Nielsen, J.M., Kristiansen, S.B., Nørregaard, R., Andersen, C.L., Denner, L., Nielsen, T.T. et al. (2009) Blockage of receptor for advanced glycation end products prevents development of cardiac dysfunction in db/db type 2 diabetic mice. Eur. J. Heart Fail. 11, 638-647
150. Deluyker, D., Ferferieva, V., Noben, J.-P., Swennen, Q., Bronckaers, A., Lambrichts, I. et al. (2016) Cross-linking versus RAGE: How do high molecular weight advanced glycation products induce cardiac dysfunction. Int. J. Cardiol. 210, 100-108
151. Asif, M., Egan, J., Vasan, S., Jyothirmayi, G.N., Masurekar, M.R., Lopez, S. et al. (2000) An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness. Proc. Natl. Acad. Sci. U.S.A. 97, 2809-2813
152. van Heerebeek, L., Hamdani, N., Handoko, M.L., Falcao-Pires, I., Musters, R.J., Kupreishvili, K. et al. (2008) Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 117, 43-51
153. Avendano, G.F., Agarwal, R.K., Bashey, R.I., Lyons, M.M., Soni, B.J., Jyothirmayi, G.N. et al. (1999) Effects of glucose intolerance on myocardial function and collagen-linked glycation. Diabetes 48, 1443-1447
154. Vaitkevicius, P.V., Lane, M., Spurgeon, H., Ingram, D.K., Roth, G.S., Egan, J.J. et al. (2001) A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys. Proc. Natl. Acad. Sci. U.S.A. 98, 1171-1175
155. Chang, K.-C., Hsu, K.-L., Chou, T.-F., Lo, H.-M. and Tseng, Y.-Z. (2004) Aminoguanidine prevents age-related deterioration in left ventricular-arterial coupling in Fisher 344 rats. Br. J. Pharmacol. 142, 1099-1104
156. Hartog, J.W.L., Voors, A.A., Bakker, S.J.L., Smit, A.J. and van Veldhuisen, D.J. (2007) Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications. Eur. J. Heart Fail. 9, 1146-1155
157. Smit, A.J., Hartog, J.W.L., Voors, A.A. and van Veldhuisen, D.J. (2008) Advanced glycation endproducts in chronic heart failure. Ann. N.Y. Acad. Sci. 1126, 225-230
158. Willemsen, S., Hartog, J.W.L., Heiner-Fokkema, M.R., van Veldhuisen, D.J. and Voors, A.A. (2012) Advanced glycation end-products, a pathophysiological pathway in the cardiorenal syndrome. Heart Fail. Rev. 17, 221-228
159. Campbell, D.J., Somaratne, J.B., Jenkins, A.J., Prior, D.L., Yii, M., Kenny, J.F. et al. (2011) Impact of type 2 diabetes and the metabolic syndrome on myocardial structure and microvasculature of men with coronary artery disease. Cardiovasc. Diabetol. 10, 80
160. Donaldson, C., Taatjes, D.J., Zile, M., Palmer, B., VanBuren, P., Spinale, F. et al. (2010) Combined immunoelectron microscopic and computer-assisted image analyses to detect advanced glycation end-products in human myocardium. Histochem. Cell Biol. 134, 23-30
161. Nozyński, J., Zakliczyński, M., Konecka-Mrowka, D., Zielinska, T., Zakliczynska, H., Nikiel, B. et al. (2012) Advanced glycation end product accumulation in the cardiomyocytes of heart failure patients with and without diabetes. Ann. Transplant. 17, 53-61
162. Nin, J.W., Jorsal, A., Ferreira, I., Schalkwijk, C.G., Prins, M.H., Parving, H.-H. et al. (2011) Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes Care 34, 442-447
163. Kilhovd, B.K., Juutilainen, A., Lehto, S., Rönnemaa, T., Torjesen, P.A., Hanssen, K.F. et al. (2007) Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population-based 18 year follow-up study. Diabetologia 50, 1409-1417
164. Semba, R.D., Bandinelli, S., Sun, K., Guralnik, J.M. and Ferrucci, L. (2009) Plasma carboxymethyl-lysine, an advanced glycation end product, and all-cause and cardiovascular disease mortality in older community-dwelling adults. J. Am. Geriatr. Soc. 57, 1874-1880
165. Sell, D.R., Sun, W., Gao, X., Strauch, C., Lachin, J.M., Cleary, P.A. et al. (2016) Skin collagen fluorophore LW-1 versus skin fluorescence as markers for the long-term progression of subclinical macrovascular disease in type 1 diabetes. Cardiovasc. Diabetol. 15, 30
166. Hartog, J.W.L., Hummel, Y.M., Voors, A.A., Schalkwijk, C.G., Miyata, T., Huisman, R.M. et al. (2008) Skin-autofluorescence, a measure of tissue advanced glycation end-products (AGEs), is related to diastolic function in dialysis patients. J. Card. Fail. 14, 596-602
167. Nenna, A., Nappi, F., Avtaar Singh, S.S., Sutherland, F.W., Di Domenico, F., Chello, M. et al. (2015) Pharmacologic approaches against advanced glycation end products (AGEs) in diabetic cardiovascular disease. Res. Cardiovasc. Med. 4, e26949
168. Cai, W., He, J.C., Zhu, L., Chen, X., Zheng, F., Striker, G.E. et al. (2008) Oral glycotoxins determine the effects of calorie restriction on oxidant stress, age-related diseases, and lifespan. Am. J. Pathol. 173, 327-336
169. Yan, S.F., Ramasamy, R. and Schmidt, A.M. (2010) The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ. Res. 106, 842-853
170. Cohen, M.M. (2013) Perspectives on RAGE signaling and its role in cardiovascular disease. Am. J. Med. Genet. A 161A, 2750-2755
171. Ma, H., Li, S.-Y., Xu, P., Babcock, S.A., Dolence, E.K., Brownlee, M. et al. (2009) Advanced glycation endproduct (AGE) accumulation and AGE receptor (RAGE) up-regulation contribute to the onset of diabetic cardiomyopathy. J. Cell Mol. Med. 13, 1751-1764
172. Yuan, Q., Zhou, Q.-Y., Liu, D., Yu, L., Zhan, L., Li, X.-J. et al. (2014) Advanced glycation end-products impair Na+ /K+ -ATPase activity in diabetic cardiomyopathy: role of the adenosine monophosphate-activated protein kinase/sirtuin 1 pathway. Clin. Exp. Pharmacol. Physiol. 41, 127-133
173. Li, S.-Y., Sigmon, V.K., Babcock, S.A. and Ren, J. (2007) Advanced glycation endproduct induces ROS accumulation, apoptosis, MAP kinase activation and nuclear O-GlcNAcylation in human cardiac myocytes. Life Sci. 80, 1051-1056
174. Daffu, G., del Pozo, C.H., O'Shea, K.M., Ananthakrishnan, R., Ramasamy, R. and Schmidt, A.M. (2013) Radical roles for RAGE in the pathogenesis of oxidative stress in cardiovascular diseases and beyond. Int. J. Mol. Sci. 14, 19891-1910
175. Diguet, N., Mallat, Y., Ladouce, R., Clodic, G., Prola, A., Tritsch, E. et al. (2011) Muscle creatine kinase deficiency triggers both actin depolymerization and desmin disorganization by advanced glycation end products in dilated cardiomyopathy. J. Biol. Chem. 286, 35007-35019
176. Nelson, M.B., Swensen, A.C., Winden, D.R., Bodine, J.S., Bikman, B.T. and Reynolds, P.R. (2015) Cardiomyocyte mitochondrial respiration is reduced by receptor for advanced glycation end-product signaling in a ceramide-dependent manner. Am. J. Physiol. Heart Circ. Physiol. 309, H63-H69
177. Bakala, H., Hamelin, M., Mary, J., Borot-Laloi, C. and Friguet, B. (2012) Catalase, a target of glycation damage in rat liver mitochondria with aging. Biochim. Biophys. Acta 1822, 1527-1534
178. Bakala, H., Ladouce, R., Baraibar, M.A. and Friguet, B. (2013) Differential expression and glycative damage affect specific mitochondrial proteins with aging in rat liver. Biochim. Biophys. Acta 1832, 2057-2067
179. Lo, M.-C., Chen, M.-H., Lee, W.-S., Lu, C.-I., Chang, C.-R., Kao, S.-H. et al. (2015) Ne-(carboxymethyl) lysine-induced mitochondrial fission and mitophagy cause decreased insulin secretion from ß-cells. Am. J. Physiol. Endocrinol. Metab. 309, E829E-E839
180. Dorn, G.W. (2015) Mitochondrial dynamism and heart disease: changing shape and shaping change. EMBO Mol. Med. 7, 865-877
181. Smith, M.A., Taneda, S., Richey, P.L., Miyata, S., Yan, S.D., Stern, D. et al. (1994) Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc. Natl. Acad. Sci. U.S.A. 91, 5710-5714
182. Münch, G., Thome, J., Foley, P., Schinzel, R. and Riederer, P. (1997) Advanced glycation endproducts in ageing and Alzheimer's disease. Brain Res. Brain Res. Rev. 23, 134-143
183. Takeuchi, M. and Yamagishi, S. (2009) Involvement of toxic AGEs (TAGE) in the pathogenesis of diabetic vascular complications and Alzheimer's disease. J. Alzheimers Dis. 16, 845-858
184. Angeloni, C., Zambonin, L. and Hrelia, S. (2014) Role of methylglyoxal in Alzheimer's disease. BioMed. Res. Int. 2014, 238485
185. Shuvaev, V.V., Laffont, I., Serot, J.M., Fujii, J., Taniguchi, N. and Siest, G. (2001) Increased protein glycation in cerebrospinal fluid of Alzheimer's disease. Neurobiol. Aging 22, 397-402
186. Kuhla, B., Lüth, H.-J., Haferburg, D., Boeck, K., Arendt, T. and and Münch, G. (2005) Methylglyoxal, glyoxal, and their detoxification in Alzheimer's disease. Ann. N.Y. Acad. Sci. 1043, 211-216
187. Southern, L., Williams, J. and Esiri, M.M. (2007) Immunohistochemical study of N-epsilon-carboxymethyl lysine (CML) in human brain: relation to vascular dementia. BMC Neurol. 7, 35
188. Srikanth, V., Westcott, B., Forbes, J., Phan, T.G., Beare, R., Venn, A. et al. (2013) Methylglyoxal, cognitive function and cerebral atrophy in older people. J. Gerontol. A Biol. Sci. Med. Sci. 68, 68-73
189. Rahmadi, A., Steiner, N. and Münch, G. (2011) Advanced glycation endproducts as gerontotoxins and biomarkers for carbonyl-based degenerative processes in Alzheimer's disease. Clin. Chem. Lab. Med. 49, 385-391
190. Vitek, M.P., Bhattacharya, K., Glendening, J.M., Stopa, E., Vlassara, H., Bucala, R. et al. (1994) Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 91, 4766-4770
191. Fawver, J.N., Schall, H.E., Petrofes Chapa, R.D., Zhu, X. and Murray, I.V.J. (2012) Amyloid-ß metabolite sensing: biochemical linking of glycation modification and misfolding. J. Alzheimers Dis. 30, 63-73
192. Kimura, T., Takamatsu, J., Araki, N., Goto, M., Kondo, A., Miyakawa, T. et al. (1995) Are advanced glycation end-products associated with amyloidosis in Alzheimer's disease. NeuroReport 6, 866-868
193. Leibson, C.L., Rocca, W.A., Hanson, V.A., Cha, R., Kokmen, E., O'Brien, P.C. et al. (1997) Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am. J. Epidemiol. 145, 301-308
194. Whitmer, R.A. (2007) Type 2 diabetes and risk of cognitive impairment and dementia. Curr. Neurol. Neurosci. Rep. 7, 373-380
195. Ohara, T., Doi, Y., Ninomiya, T., Hirakawa, Y., Hata, J., Iwaki, T. et al. (2011) Glucose tolerance status and risk of dementia in the community: the Hisayama study. Neurology 77, 1126-1134
196. Ott, A., Stolk, R.P., van Harskamp, F., Pols, H.A., Hofman, A. and Breteler, M.M. (1999) Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 53, 1937-1942
197. Beeri, M.S., Silverman, J.M., Davis, K.L., Marin, D., Grossman, H.Z., Schmeidler, J. et al. (2005) Type 2 diabetes is negatively associated with Alzheimer's disease neuropathology. J. Gerontol. A Biol. Sci. Med. Sci. 60, 471-475
198. Arvanitakis, Z., Schneider, J.A., Wilson, R.S., Li, Y., Arnold, S.E., Wang, Z. et al. (2006) Diabetes is related to cerebral infarction but not to AD pathology in older persons. Neurology 67, 1960-1965
199. Ahtiluoto, S., Polvikoski, T., Peltonen, M., Solomon, A., Tuomilehto, J., Winblad, B. et al. (2010) Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study. Neurology 75, 1195-1202
200. Sonnen, J.A., Larson, E.B., Brickell, K., Crane, P.K., Woltjer, R., Montine, T.J. et al. (2009) Different patterns of cerebral injury in dementia with or without diabetes. Arch. Neurol. 66, 315-322
201. Nelson, P.T., Braak, H. and Markesbery, W.R. (2009) Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J. Neuropathol. Exp. Neurol. 68, 1-14
202. Arrieta-Cruz, I. and Gutiérrez-Juárez, R. (2016) The role of insulin resistance and glucose metabolism dysregulation in the development of Alzheimer's Disease. Rev. Invest. Cĺin. 68, 53-58
203. Gorelick, P.B., Scuteri, A., Black, S.E., Decarli, C., Greenberg, S.M., Iadecola, C. et al. (2011) Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42, 2672-2713
204. Ivan, C.S., Seshadri, S., Beiser, A., Au, R., Kase, C.S., Kelly-Hayes, M. et al. (2004) Dementia after stroke: the Framingham Study. Stroke 35, 1264-1268
205. Ramirez, A., Wolfsgruber, S., Lange, C., Kaduszkiewicz, H., Weyerer, S., Werle, J. et al. (2015) Elevated HbA1c is associated with increased risk of incident dementia in primary care patients. J. Alzheimers Dis. 44, 1203-1212
206. Pan, X., Gong, N., Zhao, J., Yu, Z., Gu, F., Chen, J. et al. (2010) Powerful beneficial effects of benfotiamine on cognitive impairment and beta-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice. Brain J. Neurol. 133 (Pt 5), 1342-1351
207. Byun, K., Bayarsaikhan, E., Kim, D., Kim, C.Y., Mook-Jung, I., Paek, S.H. et al. (2012) Induction of neuronal death by microglial AGE-albumin: implications for Alzheimer's disease. PloS One 7, e37917
208. Li, X.-H., Du, L.-L., Cheng, X.-S., Jiang, X., Zhang, Y., Lv, B.-L. et al. (2013) Glycation exacerbates the neuronal toxicity of ß-amyloid. Cell Death Dis 4, e673
209. Cai, W., Uribarri, J., Zhu, L., Chen, X., Swamy, S., Zhao, Z. et al. (2014) Oral glycotoxins are a modifiable cause of dementia and the metabolic syndrome in mice and humans. Proc. Natl. Acad. Sci. U.S.A. 111, 4940-4945
210. Yang, Y. and Song, W. (2013) Molecular links between Alzheimer's disease and diabetes mellitus. Neuroscience 250, 140-150
211. Ledesma, M.D., Bonay, P., Colaço, C. and Avila, J. (1994) Analysis of microtubule-associated protein tau glycation in paired helical filaments. J. Biol. Chem. 269, 21614-21619
212. Sasaki, N., Toki, S., Chowei, H., Saito, T., Nakano, N., Hayashi, Y. et al. (2001) Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease. Brain Res. 888, 256-262
213. Lüth, H.-J., Ogunlade, V., Kuhla, B., Kientsch-Engel, R., Stahl, P., Webster, J. et al. (2005) Age- and stage-dependent accumulation of advanced glycation end products in intracellular deposits in normal and Alzheimer's disease brains. Cereb. Cortex 15, 211-220
214. Shimizu, F., Sano, Y., Tominaga, O., Maeda, T., Abe, M. and Kanda, T. (2013) Advanced glycation end-products disrupt the blood-brain barrier by stimulating the release of transforming growth factor-ß by pericytes and vascular endothelial growth factor and matrix metalloproteinase-2 by endothelial cells in vitro. Neurobiol. Aging 34, 1902-1912
215. Candela, P., Gosselet, F., Saint-Pol, J., Sevin, E., Boucau, M.-C., Boulanger, E. et al. (2010) Apical-to-basolateral transport of amyloid-ß peptides through blood-brain barrier cells is mediated by the receptor for advanced glycation end-products and is restricted by P-glycoprotein. J. Alzheimers Dis. 22, 849-859
216. Fang, F., Lue, L.-F., Yan, S., Xu, H., Luddy, J.S., Chen, D. et al. (2010) RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease. FASEB J. 24, 1043-1055
217. Srikanth, V., Maczurek, A., Phan, T., Steele, M., Westcott, B., Juskiw, D. et al. (2011) Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease. Neurobiol. Aging 32, 763-777
218. Luo, J., Martinez, J., Yin, X., Sanchez, A., Tripathy, D. and Grammas, P. (2012) Hypoxia induces angiogenic factors in brain microvascular endothelial cells. Microvasc. Res. 83, 138-145
219. Glass, C.K., Saijo, K., Winner, B., Marchetto, M.C. and Gage, F.H. (2010) Mechanisms underlying inflammation in neurodegeneration. Cell 140, 918-934
220. Fioravanzo, L., Venturini, M., Di Liddo, R., Liddo, R.D., Marchi, F., Grandi, C. et al. (2010) Involvement of rat hippocampal astrocytes in ß-amyloid-induced angiogenesis and neuroinflammation. Curr. Alzheimer Res. 7, 591-601
221. Yang, S.-P., Bae, D.-G., Kang, H.J., Gwag, B.J., Gho, Y.S. and Chae, C.-B. (2004) Co-accumulation of vascular endothelial growth factor with beta-amyloid in the brain of patients with Alzheimer's disease. Neurobiol. Aging 25, 283-290
222. Deane, R., Singh, I., Sagare, A.P., Bell, R.D., Ross, N.T., LaRue, B. et al. (2012) A multimodal RAGE-specific inhibitor reduces amyloid ß-mediated brain disorder in a mouse model of Alzheimer disease. J. Clin. Invest. 122, 1377-1392
223. Thomas, M.C., Forbes, J.M. and Cooper, M.E. (2005) Advanced glycation end products and diabetic nephropathy. Am. J. Ther. 12, 562-572
224. Turgut, F. and Bolton, W.K. (2010) Potential new therapeutic agents for diabetic kidney disease. Am. J. Kidney Dis. 55, 928-940
225. Abdel-Rahman, E. and Bolton, W.K. (2002) Pimagedine: a novel therapy for diabetic nephropathy. Expert Opin. Invest. Drugs 11, 565-574
226. Freedman, B.I., Wuerth, J.P., Cartwright, K., Bain, R.P., Dippe, S., Hershon, K. et al. (1999) Design and baseline characteristics for the Aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control Clin. Trials 20, 493-510
227. Lutterloh, E.C. and Opal, S.M. (2007) Antibodies against RAGE in sepsis and inflammation: implications for therapy. Expert Opin. Pharmacother. 8, 1193-1196
228. Hong, Y., Shen, C., Yin, Q., Sun, M., Ma, Y. and Liu, X. (2016) Effects of RAGE-specific inhibitor FPS-ZM1 on amyloid-ß metabolism and AGEs-induced inflammation and oxidative stress in rat hippocampus. Neurochem. Res. 41, 1192-1199
229. Gu, Q., Wang, B., Zhang, X.-F., Ma, Y.-P., Liu, J.-D. and Wang, X.-Z. (2014) Contribution of receptor for advanced glycation end products to vasculature-protecting effects of exercise training in aged rats. Eur. J. Pharmacol. 741, 186-194
230. Sabbagh, M.N., Agro, A., Bell, J., Aisen, P.S., Schweizer, E. and Galasko, D. (2011) PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 25, 206-212
231. Galasko, D., Bell, J., Mancuso, J.Y., Kupiec, J.W., Sabbagh, M.N., van Dyck, C. et al. (2014) Clinical trial of an inhibitor of RAGE-Aß interactions in Alzheimer disease. Neurology 82, 1536-1542
232. Burstein, A.H., Grimes, I., Galasko, D.R., Aisen, P.S., Sabbagh, M. and Mjalli, A.M.M. (2014) Effect of TTP488 in patients with mild to moderate Alzheimer's disease. BMC Neurol 14, 12
233. Sakatani, S., Yamada, K., Homma, C., Munesue, S., Yamamoto, Y., Yamamoto, H. et al. (2009) Deletion of RAGE causes hyperactivity and increased sensitivity to auditory stimuli in mice. PloS One 4, e8309
234. Sorci, G., Riuzzi, F., Giambanco, I. and Donato, R. (2013) RAGE in tissue homeostasis, repair and regeneration. Biochim. Biophys. Acta 1833, 101-109
235. Schmidt, A.M., Yan, S.D., Yan, S.F. and Stern, D.M. (2000) The biology of the receptor for advanced glycation end products and its ligands. Biochim. Biophys. Acta 1498, 99-111
236. Szwergold, B.S., Howell, S. and Beisswenger, P.J. (2001) Human fructosamine-3-kinase: purification, sequencing, substrate specificity, and evidence of activity in vivo. Diabetes 50, 2139-2147
237. Delpierre, G., Collard, F., Fortpied, J. and Van Schaftingen, E. (2002) Fructosamine 3-kinase is involved in an intracellular deglycation pathway in human erythrocytes. Biochem. J. 365 (Pt 3), 801-808
238. da-Cunha, M.V., Jacquemin, P., Delpierre, G., Godfraind, C., Théate, I., Vertommen, D. et al. (2006) Increased protein glycation in fructosamine 3-kinase-deficient mice. Biochem. J. 399, 257-264
239. Miller, A.G., Tan, G., Binger, K.J., Pickering, R.J., Thomas, M.C., Nagaraj, R.H. et al. (2010) Candesartan attenuates diabetic retinal vascular pathology by restoring glyoxalase-I function. Diabetes 59, 3208-3215
240. Nagaraj, R.H., Sarkar, P., Mally, A., Biemel, K.M., Lederer, M.O. and Padayatti, P.S. (2002) Effect of pyridoxamine on chemical modification of proteins by carbonyls in diabetic rats: characterization of a major product from the reaction of pyridoxamine and methylglyoxal. Arch. Biochem. Biophys. 402, 110-119
241. Cheng, A.-S., Cheng, Y.-H., Chiou, C.-H. and Chang, T.-L. (2012) Resveratrol upregulates nrf2 expression to attenuate methylglyoxal-induced insulin resistance in Hep G2 cells. J. Agric. Food Chem. 60, 9180-9187
242. Xue, M., Weickert, M.O., Qureshi, S., Kandala, N-B, Anwar, A., Waldron, M. et al. (2016) Improved glycemic control and vascular function in overweight and obese subjects by glyoxalase 1 inducer formulation. Diabetes 65, 2282-2294
243. Schmidt, A.M. (2015) Soluble RAGEs-prospects for treating & tracking metabolic and inflammatory disease. Vasc. Pharmacol. 72, 1-8
244. Hudson, B.I., Carter, A.M., Harja, E., Kalea, A.Z., Arriero, M., Yang, H. et al. (2008) Identification, classification, and expression of RAGE gene splice variants. FASEB J. 22, 1572-1580
245. Raucci, A., Cugusi, S., Antonelli, A., Barabino, S.M., Monti, L., Bierhaus, A. et al. (2008) A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J. 22, 3716-3727
246. Goova, M.T., Li, J., Kislinger, T., Qu, W., Lu, Y., Bucciarelli, L.G. et al. (2001) Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am. J. Pathol. 159, 513-525
247. Lalla, E., Lamster, I.B., Feit, M., Huang, L., Spessot, A., Qu, W. et al. (2000) Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice. J. Clin. Invest. 105, 1117-1124
248. Liu, Y., Yu, M., Zhang, Z., Yu, Y., Chen, Q., Zhang, W. et al. (2016) Blockade of receptor for advanced glycation end products protects against systolic overload-induced heart failure after transverse aortic constriction in mice. Eur. J. Pharmacol. 791, 535-543
249. Zeng, S., Feirt, N., Goldstein, M., Guarrera, J., Ippagunta, N., Ekong, U. et al. (2004) Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice. Hepatology 39, 422-432
250. Lanati, N., Emanuele, E., Brondino, N. and Geroldi, D. (2010) Soluble RAGE-modulating drugs: state-of-the-art and future perspectives for targeting vascular inflammation. Curr. Vasc. Pharmacol. 8, 86-92